Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions

Andrade, Chittaranjan

doi:10.4088/jcp.16f11128

Cited by 10 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,7 Psychiatrists who advise metformin therefore need to be aware about important common and uncommon adverse effects of the drug. This article specifically examines gastrointestinal adverse effects of metformin, the risk of lactic acidosis with metformin, and possible vitamin B 12 deficiency associated with long-term use of metformin.…”

Section: Metformin In Psychiatrymentioning

confidence: 99%

Use of Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know Safety Issues

Andrade

2016

J. Clin. Psychiatry

Self Cite

View full text Add to dashboard Cite

Section: Metformin In Psychiatrymentioning

confidence: 99%

Use of Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know Safety Issues

Andrade

2016

J. Clin. Psychiatry

Self Cite

View full text Add to dashboard Cite

“…Antipsychotic drugs are considered the primary treatment for schizophrenia. Although these drugs have significant benefits for psychotic symptoms, they can induce health problems such as metabolic syndrome, cardiovascular diseases, sexual dysfunction, and osteoporosis ( Andrade, 2016 ). Previous studies have demonstrated that patients with schizophrenia have a higher risk of osteoporosis than the general population ( Cui et al, 2018 ; Stubbs et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study

Chen

Zhang

Fan

et al. 2021

PeerJ

View full text Add to dashboard Cite

Objective Patients with schizophrenia are at increased risk of osteoporosis. This study first determined the osteoporosis rate in patients with schizophrenia and then then explored the association between serum gonadal hormone levels and osteoporosis among these patients. Methods A total of 250 patients with schizophrenia and 288 healthy controls were recruited. Osteoporosis was defined by decreased bone mineral density (BMD) of the calcaneus. Serum fasting levels of gonadal hormones (prolactin, estradiol, testosterone, progesterone, follicle-stimulating hormone, luteinizing hormone) were determined. The relationship between osteoporosis and hormone levels was statistically analyzed by binary logistic regression analysis. Results Our results showed that patients with schizophrenia had a markedly higher rate of osteoporosis (24.4% vs. 10.1%) than healthy controls (P < 0.001). Patients with osteoporosis were older, had a longer disease course, and had a lower body mass index (BMI) than patients without osteoporosis (all P < 0.05). Regarding gonadal hormones, we found significantly higher prolactin, but lower estradiol, levels in patients with osteoporosis than in those without osteoporosis (both P < 0.05). The regression analysis revealed that PRL (OR = 1.1, 95% CI [1.08–1.15], P < 0.001) and E2 level (OR = 0.9, 95%CI [0.96–0.99], P = 0.011) were significantly associated with osteoporosis in patients with schizophrenia. Conclusion Our results indicate that patients with schizophrenia who are being treated with risperidone have a high rate of osteoporosis. Increased prolactin and reduced estradiol levels are significantly associated with osteoporosis.

show abstract

“…Antipsychotic drugs are considered the primary treatment for schizophrenia. Although these drugs have significant benefits for psychotic symptoms, they can induce health problems such as metabolic syndrome, cardiovascular diseases, sexual dysfunction, and osteoporosis 6 . Previous studies have demonstrated that patients with schizophrenia have a higher risk of osteoporosis than the general population 2,7 .…”

Section: Introductionmentioning

confidence: 99%

Peer Review #1 of "Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study (v0.2)"

2021

View full text Add to dashboard Cite

Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions

Cited by 10 publications

References 9 publications

Use of Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know Safety Issues

Use of Metformin for Cardiometabolic Risks in Psychiatric Practice: Need-to-Know Safety Issues

Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study

Peer Review #1 of "Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study (v0.2)"

Contact Info

Product

Resources

About